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Abstract
Background: diagnosis of mild cognitive impairment (MCI) typically excludes individuals with medical co-morbidity.
Interest in MCI screening raises the questions of what are the best criteria to identify a representative sample and what
factors are associated with MCI progression to dementia.
Objectives: to compare the pattern of disease co-morbidity across different cognitive groups and to examine the role of
health co-morbidity as a risk factor for dementia progression from MCI.
Methods: individuals from the MRC Cognitive Function and Ageing Study were classiﬁed as having no cognitive impair-
ment (NCI), MCI, other cognitive impairment no dementia (OCIND) or dementia. At 2 years dementia status was
assessed.
Findings: over 50% of individuals in each group reported one or more medical condition. The pattern of disease preva-
lence was similar in the NCI, MCI and OCIND groups. Anaemia was the only health factor associated with an increased
risk of dementia progression from MCI.
Conclusion: classiﬁcation of MCI using medical exclusions would exclude the majority of the population from a MCI diag-
nosis. This has implications for treatment decisions and clinical trial recruitment. This could not only make recruitment
more difﬁcult but also limit the generalisability of trial results. Medical co-morbidity does not help to distinguish progressive
from non-progressive MCI.
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Introduction
Poor health has been associated with an increased risk of
cognitive decline and may also be a risk factor for
Alzheimer’s disease (AD) and vascular dementia.
Examining health status in cognitively impaired older adults
may be important in identifying the underlying pathogen-
esis of cognitive decline, and if helpful in predicting demen-
tia risk might be relevant to the development of strategies
to delay the onset of dementia. Accounting for health and
its risk factors in cognitively impaired older individuals is
also important for clinical trial enrolment and decision-
making about treatment, particularly in the presence of
co-morbidity given the risks associated with polypharmacy.
The term mild cognitive impairment (MCI) is widely
used to describe a state of increased dementia risk between
ageing without impaired cognitive function and dementia.
Although not always explicitly stated a MCI diagnosis is
often made following medical exclusion [1–3]. In screening
protocols however, the exclusion of co-morbid conditions
501may adversely affect selection of the population at risk.
Interest in screening for MCI raises the question of what
are the best eligibility criteria to identify a representative
MCI sample. While clinically signiﬁcant medical abnormal-
ities can compromise participant safety, expose individuals
to undue risk or signiﬁcantly interfere with trial procedures
and outcomes, too strict inclusion criteria can affect sample
representativeness (to the population at risk) and trial val-
idity. The implication of medical exclusion on case diagno-
sis is not known and determining the representativeness of
participants selected for trials requires knowledge of disease
prevalence in the general population and in individuals with
MCI. Furthermore determining those individuals in whom
cognitive impairment can be ameliorated through alternative
channels such as uncompensated diabetes, hyperthyroidism
or hyponatraemia is important for exclusion from clinical
trials.
The annual conversion rate from MCI to dementia
varies from 5 to 10% according to the deﬁnition used. Not
all individuals with MCI progress to dementia, with some
individuals remaining stable or reverting to normal [4, 5].
Markers are now being sought to distinguish progressive
from non-progressive forms of MCI. Longitudinal studies
have found that poor health in mid-life can increase risk of
cognitive decline and dementia in late life [6, 7]. In some
studies, poor health is found to elevate risk of dementia
progression from MCI [8–10]. Associations are not always
robust, however, and may depend on the timing of health
measurement (mid-life versus later life), study sample
(clinic versus population based) and MCI diagnostic criteria
(amnestic versus non-amnestic). Whether poor health status
can be used to inform the subdivision between progressive
and non-progressive MCI may be of value in deﬁning
dementia risk in MCI cohorts.
The aim of this study is to compare the pattern of
major disease co-morbidity across the spectrum of
age-associated cognitive changes including normal, MCI,
OCIND and demented groups. We also examined the role
of health co-morbidity as a risk factor for 2-year incident
dementia across the different cognitive states.
Methods
Participants
Participants were from MRC CFAS (see http://www.cfas.ac.
uk) [11]. Baseline interviewing began in 1991. Individuals
aged 65 years or older were randomly selected from the
Family Health Service Authority lists in ﬁve areas of the
UK including centres in Cambridgeshire, Gwynedd,
Newcastle, Nottingham and Oxford. In total, 13,004 par-
ticipants completed the screening interview undertaken by a
trained interviewer at the participants’ place of residence.
Information on demographic and socio-demographic
status, functional ability, self report health status and cogni-
tive performance measured using the Mini Mental State
Examination (MMSE) [12], and selected items from the
Geriatric Mental State (GMS) Automated Geriatric
Examination for Computer-Assisted Taxonomy
(AGECAT) [13] were collected. A sub-sample of approxi-
mately 20% (n = 2,640) of respondents were selected based
on age, centre and cognitive ability to complete a more
detailed assessment. This included the organicity sections
of the AGECAT and the Cambridge Cognitive
Examination (CAMCOG) [14]. All individuals were also
asked to provide details of an informant, and the History
and Aetiology Schedule was completed for as many as
possible. The study was approved by the local ethics com-
mittee for each centre and informed consent obtained from
all participants before interview. Data from the initial preva-
lence screen, ﬁrst assessment and 2-year follow-up inter-
views (Data Version 8.2) were used in this analysis.
Health co-morbidity index
Health status was determined based on self or an infor-
mant report of the presence of a condition. From the base-
line interview 10 conditions common in the older
population were selected including: pernicious anaemia,
Parkinson’s disease (PD), breathing difﬁculties, angina,
hypertension, diabetes mellitus, peripheral vascular disease
(PVD: intermittent claudication), transient ischaemic attack
(TIA), self-reported history of stroke or heart attack.
Angina and PVD were derived from the Rose Angina Scale
[15]. A co-morbidity score (range 0–10) was deﬁned as the
number of health conditions present.
Dementia
Dementia status was derived using the full AGECAT diag-
nostic algorithm [13], deﬁned as an AGECAT organicity
rating case level of 3 or above. This is reported to be equiv-
alent to dementia as diagnosed using the Diagnostic and
Statistical Manual of Mental Disorders, Third Edition, Revised
(DSM-III-R) [16, 17]. In total, 8.8% (9.8% age standardised
rate) had a case level diagnosis of dementia with a pro-
portion of this group with other psychiatric co-morbidity.
MCI definition
A diagnosis of MCI was made based on revised Mayo
Clinic criteria for MCI which combines the A-MCI, non-
amnestic MCI (N-MCI) and multiple MCI (M-MCI) sub-
types [18, 19]. Full details of the criteria for mapping each
subtype in CFAS have been reported previously [20],
although in the present study mapping was modiﬁed in that
no medical exclusions were applied. At ﬁrst assessment
individuals without dementia were classiﬁed into three
groups including: (i) MCI; (ii) NCI or (iii) OCIND. For
classiﬁcation of MCI individuals had to be non-demented
and fulﬁl the following criteria: (i) subjective/informant
complaint of memory loss; (ii) normal general cognitive
function (MMSE ≥22); (iii) no severe functional impair-
ment (deﬁned as requiring help at least several times per
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ual was housebound) and, (4) objective memory and/or
non-memory impairment (based on age-adjusted
CAMCOG cut-off values derived from composite memory
and non-memory scores). To be classiﬁed as NCI, individ-
uals had to fulﬁl the following criteria: (i) normal general
cognitive functioning; (ii) no severe functional impairment;
(iii) normal memory and non-memory test performance
and (iv) not demented. The OCIND group included all
non-normal individuals who failed to fulﬁl MCI criteria
[21]. At ﬁrst assessment interview 608 individuals fulﬁlled
criteria for NCI, 319 MCI and 580 OCIND.
Analysis
Summary statistics (means and medians, weighted for study
design) were used to compare baseline demographic charac-
teristics across cognitive groups. ANOV Awas used to test for
group differences in age, cognitive status (MMSE) and edu-
cational attainment. The population prevalence (95% conﬁ-
dence interval: 95% CI) of each health condition stratiﬁed by
cognitive status was calculated. Group differences in disease
prevalence were tested using the Chi-squared statistic. Post hoc
comparisons of prevalence were tested using logistic
regression weighted for study design, with the MCI group as
the referent. The pattern of disease and medical co-morbidity
was also examined in the A-MCI, N-MCI and M-MCI
groups to test whether collapsing across each subtype to
form the MCI group was driving the results. Age standar-
dised prevalence estimates were also calculated using 5-year
age groups (including 64–69, 70–74, 75–79, 80–84 and 85+
years). This controlled for the baseline differences in the age
structure across the different cognitive groups. The
association between each health condition and dementia pro-
gression was evaluated using univariate and multivariate (age,
gender and education) logistic regression models (weighted
for attrition) in the NCI, MCI and OCIND groups. Analyses
were undertaken using Stata Version 10.0.
Results
Socio-demographic characteristics
Baseline prevalence and socio-demographic characteristics
for each cognitive group by disease co-morbidity status are
shown in Table 1. Most of the sample (50.1%, back-
weighted) was not cognitively impaired. Overall, the demen-
tia group was the oldest in both the disease and no-disease
co-morbidity conditions (all P<0.0001). There were no
other group differences in age. In both the disease and
no-disease co-morbidity conditions the NCI group had a
higher level of education than all other groups.
Health co-morbidity across cognitive groups
Table 2 shows the prevalence of each health condition in
the NCI, MCI, OCIND and dementia groups. Age stan-
dardisation did not substantially change prevalence esti-
mates (data not shown) and unstandardised estimates are
used for all further analysis. Overall, hypertension was the
most common condition, being present in over 20% of
individuals in each cognitive group. PD was the least
common condition being present in less than 5% of indi-
viduals in each cognitive group. There was a high degree of
similarity in disease prevalence across the different cognitive
groups, except that stroke and PD were signiﬁcantly more
....................................................................................
Table 1. Baseline demographic characteristics (weighted for study design) of the different cognitive groups stratified by
disease status (including those individuals who do not report any of the health conditions and individuals who report one
or more of the health conditions)
NCI (n=608) MCI (n=319) OCIND (n= 580) Dementia (n=587)
a
Population prevalence (95% CI) 50.1 (47.1–53.2) 16.4 (14.3–18.8) 24.7 (22.2–27.3) 8.8 (7.8–9.8)
Age standardised prevalence (95% CI) 43.6 (40.8–46.4) 14.5 (12.5–16.4) 21.5 (19.3–23.7) 7.7 (6.6–8.6)
% Progressed to dementia at 2 years (95% CI) 0.7 (0.3–1.5) 5.6 (3.0–10.0) 7.7 (4.2–13.8) ——
No health conditions
Mean age (q1, q3), years 72.6* (68,76) 74.2* (68,79) 73.0* (68,78) 81.9 (79,87)
Mean education (q1, q3), years 11.1* (9,12) 9.9*
,** (9,10) 9.5** (9,10) 9.7 (9,10)
% Female (n)
b 54.0 (141) 58.4 (68) 57.6 (143) 73.2 (111)
Mean MMSE [q2 (q1,q3)] 27.6* 28 (26,29) 26.1*
,** 27 (25,28) 25.4*
,** 26 (23,28) 20.1** 20 (17,24)
One or more health conditions
Mean age (q1, q3), years 73.5* (69,78) 72.5* (68,77) 73.0* (68,76) 79.8 (74,84)
Mean education (q1, q3), years 10.4 (9,11) 9.6** (9,10) 9.6** (9,10) 9.1** (9,9)
% Female (n)
b 54.2 (204) 53.3 (126) 60.6 (226) 60.1 (101)
Mean MMSE [q2 (q1,q3)] 27.4* 28 (26,29) 26.2*
,** 27 (25,28) 25.4*
,** 26 (23,28) 19.3** 19 (16,22)
All estimates (means, SDs, medians and quartiles) are population weighted.
n, number of observations; q2, Quartile 2 (50th percentile); q1, Quartile 1 (25th percentile); q3, Quartile 3 (75th percentile); NCI, no cognitive impairment; MCI,
mild cognitive impairment; OCIND, other cognitive impairment no dementia.
aA proportion of which have other psychiatric co-morbidity.
bSome individuals in each group are missing the co-morbidity score.
*Significantly different from the demented group.
**Significantly different from the NCI group.
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OCIND groups had a similar pattern of disease prevalence
for all conditions. Across the different subtypes of MCI,
anaemia (t=2.91, P < 0.005) and TIA (t=2.65,
P < 0.005) were more prevalent in the M-MCI compared
with the N-MCI group. Otherwise, all other conditions
were similarly prevalent across MCI subtypes.
Multi co-morbidity
Over 50% of individuals in each cognitive group had one
or more medical conditions as shown in Table 3.T h e
pattern of co-morbidity was similar across all groups
[χ
2(18)=35.3, P > 0.05].
Health and dementia risk associations across
cognitive groups
At 2 years, of the 2,640 individuals interviewed at the ﬁrst
assessment, 451 had died (219 of who were classiﬁed as
demented at the baseline interview). Of the sample of
1,641 individuals seen at the 2-year follow-up, 381 persons
were demented. In the MCI group, anaemia was the only
signiﬁcant predictor of 2-year dementia progression (unad-
justed OR=13.5, 95% CI: 2.6–71.3; adjusted for age edu-
cation and gender OR=10.6, 95% CI: 2.3–48.7). No
health factor increased risk of dementia progression in the
NCI or OCIND groups.
Discussion
The ﬁndings conﬁrm previous reports of a high prevalence
of disease co-morbidity in the older population [22]. In all
groups, fewer than 50% reported no medical conditions
with a large number of individuals reporting between one
and three conditions. Speciﬁc disease prevalence, however,
differed between the demented and non-demented groups.
Generally there was no association between single-risk
factors and incident dementia in MCI. Disease status was
predictive of 2-year incident dementia in the MCI group
only when co-morbidity was associated with anaemia.
While the pattern of disease prevalence was similar in
the NCI, MCI and OCIND groups, individuals with
dementia were more likely to have medical co-morbidity
related to stroke and PD. This is not unexpected as each of
these conditions is known to increase in incidence with age
....................................................................................
Table 2. Health profile by cognitive group (weighted for study design)
NCI (n=608) MCI (n=319) OCIND (n=580) DEM (n=587) P-value
(X
2)
Significant post hoc comparison
% 95% CI % 95% CI % 95% CI % 95% CI
Health/medical
Anaemia (n=77) 2.5 (1.4–4.5) 1.6 (0.8–3.1) 1.7 (0.8–3.4) 3.2 (1.8–5.4) 0.45 —
PD (n=37) 0.7 (0.2–2.0) 0.1 (0.0–1.0) —— 2.6 (1.4–4.8) 0.01 DEM significantly higher than the
NCI and MCI groups. No
other group differences
significant
Breathing problems (n=433) 15.5 (12.4–19.2) 18.8 (13.6–25.3) 17.2 (11.8–19.9) 16.5 (14.3–18.9) 0.64 —
Vascular conditions
Angina (n=413) 17.5 (14.2–21.4) 18.3 (13.3–24.5) 12.8 (9.5–17.1) 11.5 (8.4–15.7) 0.12 —
Hypertension (n=762) 31.0 (26.8–35.5) 29.3 (23.0–36.5) 35.0 (29.8–40.6) 20.7 (15.9–26.5) 0.08 —
Diabetes (n= 158) 3.4 (2.0–5.6) 6.6 (3.8–11.3) 5.7 (3.6–8.9) 7.1 (4.9–10.4) 0.10 —
Intermittent claudication
(n=101)
3.9 (2.4–6.3) 5.6 (2.9–10.5) 3.5 (1.9–6.4) 3.1 (1.8–5.3) 0.59 —
Ischaemic lesion-related variables
Transient ischaemic attack
(n=420)
13.8 (10.9–17.3) 17.4 (12.6–23.6) 13.6 (10.3–17.6) 13.8 (10.5–18.1) 0.49 —
Stroke (n=270) 4.9 (3.2–7.3) 7.6 (4.4–12.8) 4.8 (3.0–7.7) 18.5 (14.0–24.1) P<0.01 DEM significantly higher than the
NCI, MCI and OCIND groups.
No other group differences
significant
Heart attack (n=243) 9.5 (7.1–12.7) 8.3 (5.2–13.1) 8.4 (5.7–12.3) 6.4 (4.2–9.5) 0.69 —
NCI, no cognitive impairment; MCI, mild cognitive impairment; OCIND, other cognitive impairment no dementia; DEM, dementia.
........................................
Table 3. Percent (weighted for study design) of medical
co-morbidities in each cognitive group
NCI (n
a= 605) MCI (n
a= 315) OCIND (n
a=
574)
DEM (n
a=322)
% 95% CI % 95% CI % 95% CI % 95% CI
Co-morbidity number
0 42.6 (40.0–47.3) 39.7 (32.5–47.3) 36.9 (31.5–42.6) 48.3 (40.7–55.9)
1 28.7 (24.6–33.1) 25.8 (19.8–32.8) 39.2 (33.7–45.0) 24.3 (18.2–31.6)
2 17.4 (14.1–21.4) 21.8 (16.1–28.6) 13.4 (10.1–17.4) 15.8 (11.8–20.8)
3 7.5 (5.4–10.3) 8.2 (5.0–13.1) 6.7 (4.3–10.2) 8.0 (5.3–11.8)
4 2.4 (1.3–4.3) 4.1 (1.1–6.6) 3.0 (1.5–5.7) 2.1 (1.0–4.2)
5 1.2 (0.5–2.8) 0.3 (0.0–1.7) 0.8 (0.3–1.9) 0.9 (0.2–2.9)
6 0.3 (0.0–1.9) 0.2 (0.0–1.3) —— 0.6 (0.1–2.5)
NCI, no cognitive impairment; MCI, mild cognitive impairment; OCIND,
other cognitive impairment no dementia; DEM, dementia.
an is different due to missing health factors for some individuals.
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and each is a risk factor for incident dementia [23, 24]. It is
possible, given that medical conditions were acquired using
self-report, that prevalence estimates may reﬂect bias in
self-reporting or selective survival across groups. However,
self-report and objective disease status have been found to
be in high agreement for most of the diseases included
here [25,26].
With regard to co-morbidity, the results conﬁrm that
medical co-morbidity commonly occurs in both cognitively
preserved and cognitively impaired older individuals [27,
28]. As the speciﬁc pattern of disease prevalence was
similar in all non-demented groups, the results suggest that
the selected conditions and their pattern of co-morbidity
alone do not strongly inﬂuence the impairment captured in
the MCI and OCIND states. This is in contrast to ﬁndings
from clinical and observational studies that suggest that
disease co-morbidity associated with, for example, stroke,
hypertension, heart attack, diabetes and their co-occurrence,
increase risk for major adverse outcomes associated with
health and cognition in older adults. The individuals
studied here, however, are representative of the general
population and are not a selected group of patients.
Published research on progression from secondary and ter-
tiary level health-care systems is likely to vary due to differ-
ences in participant’sp r o ﬁle and reason for referral.
Most published MCI case deﬁnitions do not explicitly
state medical exclusion criteria although these are routinely
employed in the diagnosis of MCI and tend to relate to
psychiatric and vascular co-morbidity [3]. In clinical trials,
strict eligibility criteria are typically necessary when the iso-
lated effect of an agent is to be tested and for safety
reasons. However, the results suggest that strict eligibility
criteria could result in insufﬁcient or biased case identiﬁ-
cation as less than 50% of individuals across any group
report no medical co-morbidities. As such clinical trial
samples will not reﬂect the population for whom the treat-
ment is being sought. Trials must be designed with careful
consideration and general agreement of inclusion/exclusion
criteria for MCI, and should only be restricted to those
individuals who are most likely to be affected favourably by
the treatment [3].
An important focus of MCI research is the identiﬁcation
of improved methods of classiﬁcation to differentiate MCI
cases at risk of dementia progression from those who are
not [29]. Medical co-morbidity may affect dementia pro-
gression in MCI cohorts. It has been hypothesised that het-
erogeneity in the outcome of MCI may be linked to the
presence of co-morbid disease [30]. Previous studies have,
however, been inconclusive in identifying medical risk
factors for incident dementia in MCI groups. Only atrial
ﬁbrillation and low folate levels have been associated with
an increased risk of dementia progression in MCI [31].
Disparate results are possibly due to differences in MCI
case selection criteria, sample age (young-old versus
oldest-old), disease severity levels, measurement of risk
factors and study populations (clinic samples with ranging
emphasis versus population based). In this study, only
anaemia increased risk of dementia in individuals with
MCI. Anaemia has not, however, been consistently associ-
ated with cognitive decline and dementia risk [32, 33]: not
all studies ﬁnd an association, including a previous study
using the CFAS cohort. One possible reason for a lack of
an association in otherwise non-demented samples may be
due to a wash-out effect on the relationship when the
different cognitive groups (i.e. normal, MCI and OCIND)
are combined for analysis. Given that the prevalence of
anaemia was similar across all groups, the results suggest
that one mechanism by which anaemia impacts dementia
risk in MCI could be due to compromised compensatory
processes in the MCI state. Indeed, in MCI the pathology
underlying cognitive symptoms (e.g. AD or vascular pathol-
ogy) may make it difﬁcult for the brain to compensate for
the additional insult (i.e. low-oxygen supply) caused by the
anaemia. In contrast, in the NCI and OCIND states neuro-
pathology would be unlikely to be as great and, therefore,
compensatory mechanisms would be expected to be more
efﬁcient. This needs to be tested.
Conclusions
Medical co-morbidity is an important aspect of ageing.
There is relatively little difference across the different cogni-
tive groups apart from increased stroke and PD in demen-
tia. Trends of co-morbidity and treatment need to be
updated, especially as patterns of disease and medication
use are important considerations for clinical trial design
with regard to issues of polypharmacy and sample repre-
sentativeness. Most published MCI case deﬁnitions do not
explicitly state medical exclusion criteria although these are
routinely employed in the diagnosis of MCI and tend to
relate to psychiatric and vascular co-morbidity [3]. For clini-
cal trial enrolment although exclusion criteria are necessary
to minimise confounding, too strict inclusion may result in
a sample not reﬂective of the population for whom the
treatment is being sought. This will compromise the gener-
alisability of results. Trials should be designed for real
populations with careful consideration and general agree-
ment of inclusion/exclusion criteria for MCI.
Key points
￿ Clinical trials in older aged populations typically exclude
individuals with common medical co-morbidities.
￿ MCI sample characteristics will change depending on the
medical exclusions applied for a case diagnosis.
￿ Strict eligibility criteria could result in insufﬁcient or
biased MCI case identiﬁcation, especially in clinical trials,
restricting the generalisability of results.
￿ Medical co-morbidity does not appear to increase the risk
of dementia progression in individuals with MCI.
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Abstract
Background: many measures of Quality-of-Life (QoL) may not be suitable for older people in care homes, and do not
cover the most relevant domains for individuals.
Objective: to describe QoL of older people living in care homes using the SEIQoL-DW and the two 10-point rating
scales, and to describe how people were using these measures.
Design: we used quantitative methods to describe QoL, and qualitative methods to explore residents’ experiences of com-
pleting the measures.
Setting: three care homes in the United Kingdom.
Sample: twenty residents.
Methods: residents completed the measures in interviews. We report descriptive statistics for QoL, the most important
QoL domains for residents, completion rates and experiences of administering the instruments.
Results: the most important QoL domains identiﬁed in the SEIQoL-DW were leisure activities; family; relationships; social
life; independence and peace and contentment. Physical limitations and difﬁculty in understanding the instructions and con-
cepts made completing it a challenge. The SEIQoL index was strongly correlated with a single 10-point rating of current
QoL (rho = 0.67, P=0.007).
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